Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

NEK2 Promotes Bortezomib Resistance through Enhancing Autophagy By Upregulation of Beclin1 in Multiple Myeloma Cells

Jiliang Xia, PhD, Yanjuan He, MD, Bin Meng, Jingyu Zhang, Xuan Wu, Xiangling Feng, PhD, Chunmei Kuang, Jiaojiao Guo, Yinghong Zhu, Qian Lei, Yongjun Guan, Yi Shen, MD PhD, Lugui Qiu, MD PhD, Wen Zhou, PhD

Blood (2019) 134 (Supplement_1): 4332.

https://doi.org/10.1182/blood-2019-126617

Published: 2019

Journal Articles

Evaluation of Clinical, Hematological and Flow Cytometry Dates in Elderly Patients with Acute Myeloid Leukemia: Impact on Clinical Outcome

Alessandra Suelen Jardim Silva, Lenilton Silva DA Silva Júnior, Jr., MSc, Gustavo Henrique de Medeiros Oliveira, PhD, Antonia Eduarda Martins Oliveira Elói Silva, João Pedro Andrade Lima, Victor lima Soares, Rodrigo Villar Freitas, MD, Frank Bahia, MD, Taissa Moura Oliveira, MSc, Dany GKC Silva, Valéria SF Sales, PhD, Hugo Diogenes De Oliveira Paiva, MD, Rafael Santiago Araujo, Aldair Sousa Paiva, PhDMD, Geraldo Barroso Cavalcanti, Jr., PhD

Blood (2019) 134 (Supplement_1): 5115.

https://doi.org/10.1182/blood-2019-127319

Published: 2019

Journal Articles

MiR-143 Targets ERK5 in Granulopoiesis and Predicts Outcome of Patients with Acute Myeloid Leukemia

Jens-Uwe Hartmann, MSc, Daniela Bräuer-Hartmann, PhD, Miroslava Kardosova, MSc, Franziska Wilke, MSc, Alexander Arthur Wurm, PhD, Cindy Schoedel, MD, Dennis Gerloff, PhD, Christiane Katzerke, PhD, Rosanna H.E. Krakowsky, MSc, Carolina Yaeko Namasu, MSc, Marius Bill, Sebastian Schwind, MD, Carsten Müller-Tidow, Dietger W. Niederwieser, MD, Meritxell Alberich-Jorda, Gerhard Behre, MD

Blood (2017) 130 (Supplement 1): 3950.

https://doi.org/10.1182/blood.V130.Suppl_1.3950.3950

Published: 2017

Journal Articles

ABCG2 but Not ABCB1 RNA Levels at Diagnosis and during Treatment Correlates with Response to Imatinib and 2G-Tkis Front-Line Therapy in Chronic Phase CML Patients

Mario Tiribelli, MD, Sara Di Giusto, Eleonora Toffoletti, Davide Griguolo, Domenico Penna, Giorgia Maccari, Marta Medeot, Renato Fanin, Daniela Damiani

Blood (2017) 130 (Supplement 1): 1614.

https://doi.org/10.1182/blood.V130.Suppl_1.1614.1614

Published: 2017

Journal Articles

Novel DNA-Damaging Linker Payloads Are Active in Models of Acquired Resistance to Calicheamicin and Standard of Care

Jennifer Kahler, Maureen Dougher, Jia Lu, MS, Jane Xu, MS, Tasneem Kausar, PhD, Luanna Lemon, Wenyan Zhong, PhD, Judy Lucas, Matthew Sung, PhD, Puja Sapra, PhD

Blood (2016) 128 (22): 3522.

https://doi.org/10.1182/blood.V128.22.3522.3522

Published: 2016

Journal Articles

Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters

Joanne Mountford, PhD, Andrea Davies, Niove E Jordanides, Athina Giannoudis, Claire M Lucas, Sophia Hatziieremia, Robert J Harris, Heather G Jorgensen, Munir Pirmohamed, Tessa L Holyoake, Richard E Clark

Blood (2008) 112 (11): 3205.

https://doi.org/10.1182/blood.V112.11.3205.3205

Published: 2008

Journal Articles

Imatinib Is a Substrate for Various Multidrug Resistance Proteins

Krzysztof Czyzewski, Jan Styczynski, PhD

Blood (2008) 112 (11): 4249.

https://doi.org/10.1182/blood.V112.11.4249.4249

Published: 2008

Journal Articles

Amonafide L-Malate Bypasses Multidrug Resistance Proteins in Secondary Acute Myeloid Leukemia.

Kieran L. O’Loughlin, BS, Hans Minderman, PhD, Laurie A. Ford, BS, Maria R. Baer, MD

Blood (2007) 110 (11): 2380.

https://doi.org/10.1182/blood.V110.11.2380.2380

Published: 2007

Journal Articles

Prognostic Significance of Multidrug Resistance Proteins Expression in Acute Myeloid Leukemia.

Oleg D. Zakharov, MD, Ekaterina U. Rybalkina, Ph, D., Alla A. Stavrovskaya, Maya Volkova, MD

Blood (2006) 108 (11): 4360.

https://doi.org/10.1182/blood.V108.11.4360.4360

Published: 2006

Journal Articles

Clinical Relevance of Multidrug Resistance Proteins Expression in Patients with De Novo Acute Myeloid Leukaemia.

Maria Podolak-Dawidziak, Danuta Dus, Marek Kielbinski, Maria Paprocka, Olga Haus, Malgorzata Kuliszkiewicz-Janus, Kazimierz Kuliczkowski

Blood (2006) 108 (11): 4363.

https://doi.org/10.1182/blood.V108.11.4363.4363

Published: 2006

Journal Articles

Phase III Study of Immunotherapy with Recombinant Interleukin-2 (IL-2) Versus No Further Therapy in Acute Myeloid Leukemia (AML) Patients ≥ 60 Years in First Complete Remission (CALGB 9720).

Maria R. Baer, MD, Stephen L. George, PhD, Michael A. Caligiuri, MD, Ben L. Sanford, MS, Kieran L. O’Loughlin, MS, Krysztof Mrozek, PhD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Joseph O. Moore, MD, Richard M. Stone, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2006) 108 (11): 424.

https://doi.org/10.1182/blood.V108.11.424.424

Published: 2006

Journal Articles

Multidrug Resistance Proteins Overexpression Worsen the Favorable Clinical Impact of an Elevated Spontaneous Apoptosis in Acute Myeloid Leukemia (AML).

Giovanni Del Poeta, Maria Ilaria Del Principe, Francesco Buccisano, Adriano Venditti, Luca Maurillo, Emanuele Ammatuna, Antonio Bruno, Benedetta Neri, Chiara Sarlo, Francesco Lo Coco, Paolo de Fabritiis, Sergio Amadori

Blood (2006) 108 (11): 2315.

https://doi.org/10.1182/blood.V108.11.2315.2315

Published: 2006

Journal Articles

The Role of Multidrug Resistance Proteins and Drug Sensitivity in Relation to Poor Prognosis Identified by ZAP-70 Expression and IgV H Mutation Status in B-CLL.

S. Narat, MD, N. I. Folarin, PhD, R. J. Baker, MSc, V. Duke, PhD, B. C. Yogashangary, BSc, D. T. Jones, PhD, S. M. Hart, PhD, R. G. Wickremasinghe, PhD, A. Victor Hoffbrand, DSc, A. B. Mehta, MD, L. Foroni, MD, K. Ganeshaguru, PhD

Blood (2004) 104 (11): 4791.

https://doi.org/10.1182/blood.V104.11.4791.4791

Published: 2004

Journal Articles

Cyclosporine A Modulates the Multidrug Resistance Proteins P-Glycoprotein, Multidrug Resistance Protein, Breast Cancer Resistance Protein and Lung Resistance Protein.

Misbah Qadir, MD, Kieran L. O’Loughlin, MS, Nicole A. Williamson, BA, Hans Minderman, PhD, Maria R. Baer, MD

Blood (2004) 104 (11): 1180.

https://doi.org/10.1182/blood.V104.11.1180.1180

Published: 2004

Journal Articles

The Clinical Significance of the Multidrug Resistance Proteins Expression in Patients with Acute Myeloid Leukemia.

Maria Podolak-Dawidziak, Danuta Dus, Marek Kielbinski, Maria Paprocka, Malgorzata Kuliszkowicz-Janus, Kazimierz Kuliczkowski

Blood (2004) 104 (11): 4411.

https://doi.org/10.1182/blood.V104.11.4411.4411

Published: 2004

Journal Articles

Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study

Catherine P. Leith, Kenneth J. Kopecky, I-Ming Chen, Lisette Eijdems, Marilyn L. Slovak, Thomas S. McConnell, David R. Head, James Weick, Michael R. Grever, Frederick R. Appelbaum, Cheryl L. Willman

Blood (1999) 94 (3): 1086–1099.

https://doi.org/10.1182/blood.V94.3.1086.415k32_1086_1099

Published: 1999

NARROW

NEK2 Promotes Bortezomib Resistance through Enhancing Autophagy By Upregulation of Beclin1 in Multiple Myeloma Cells

Evaluation of Clinical, Hematological and Flow Cytometry Dates in Elderly Patients with Acute Myeloid Leukemia: Impact on Clinical Outcome

MiR-143 Targets ERK5 in Granulopoiesis and Predicts Outcome of Patients with Acute Myeloid Leukemia

ABCG2 but Not ABCB1 RNA Levels at Diagnosis and during Treatment Correlates with Response to Imatinib and 2G-Tkis Front-Line Therapy in Chronic Phase CML Patients

Novel DNA-Damaging Linker Payloads Are Active in Models of Acquired Resistance to Calicheamicin and Standard of Care

Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters

Imatinib Is a Substrate for Various Multidrug Resistance Proteins

Amonafide L-Malate Bypasses Multidrug Resistance Proteins in Secondary Acute Myeloid Leukemia.

Prognostic Significance of Multidrug Resistance Proteins Expression in Acute Myeloid Leukemia.

Clinical Relevance of Multidrug Resistance Proteins Expression in Patients with De Novo Acute Myeloid Leukaemia.

Phase III Study of Immunotherapy with Recombinant Interleukin-2 (IL-2) Versus No Further Therapy in Acute Myeloid Leukemia (AML) Patients ≥ 60 Years in First Complete Remission (CALGB 9720).

Multidrug Resistance Proteins Overexpression Worsen the Favorable Clinical Impact of an Elevated Spontaneous Apoptosis in Acute Myeloid Leukemia (AML).

The Role of Multidrug Resistance Proteins and Drug Sensitivity in Relation to Poor Prognosis Identified by ZAP-70 Expression and IgV H Mutation Status in B-CLL.

Cyclosporine A Modulates the Multidrug Resistance Proteins P-Glycoprotein, Multidrug Resistance Protein, Breast Cancer Resistance Protein and Lung Resistance Protein.

The Clinical Significance of the Multidrug Resistance Proteins Expression in Patients with Acute Myeloid Leukemia.

Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only